SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Pathogenesis(pgns)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Mel Spivak who wrote (115)11/22/1998 1:33:00 PM
From: DJ  Read Replies (2) of 228
 
The Wall Street Journal had a front-page article last Thursday, Nov 19, profiling the CEO of a small Colorado hospital who suffers from cystic fibrosis and who has benefited enormously from Pathogenesis' new drug, Tobi. While the thesis of the article was the hospital CEO's conflict between the need to control drug costs and the fact that this (expensive) new drug is lengthening his life, the fact that companies such as PGNS are successfully developing drugs for chronic lung diseases isn't being lost on some investors.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News